-
Mashup Score: 40Books | European Respiratory Society - 16 hour(s) ago
If you have a myERS account, please click the button above to login. Not sure if your membership is up to date? Check at my. ersnet.org
Source: publications.ersnet.orgCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 40Books | European Respiratory Society - 2 day(s) ago
If you have a myERS account, please click the button above to login. Not sure if your membership is up to date? Check at my. ersnet.org
Source: publications.ersnet.orgCategories: General Medicine News, PulmonologyTweet-
Lung transplantation (LTx) may be considered in end-stage COPD. Survival benefit is often equivocal, and LTx should be reserved for those who do not respond to optimised therapy. Multisystem evaluation and lifelong surveillance is vital. @MarkGreerMD https://t.co/Zg2Y102SoJ https://t.co/KMiTvpTG4I
-
-
Mashup Score: 40Books | European Respiratory Society - 3 day(s) ago
If you have a myERS account, please click the button above to login. Not sure if your membership is up to date? Check at my. ersnet.org
Source: publications.ersnet.orgCategories: General Medicine News, PulmonologyTweet-
Lung transplantation (LTx) may be considered in end-stage COPD. Survival benefit is often equivocal, and LTx should be reserved for those who do not respond to optimised therapy. Multisystem evaluation and lifelong surveillance is vital. @MarkGreerMD https://t.co/Zg2Y102SoJ https://t.co/KMiTvpTG4I
-
-
Mashup Score: 40Books | European Respiratory Society - 4 day(s) ago
If you have a myERS account, please click the button above to login. Not sure if your membership is up to date? Check at my. ersnet.org
Source: publications.ersnet.orgCategories: General Medicine News, PulmonologyTweet-
Lung transplantation (LTx) may be considered in end-stage COPD. Survival benefit is often equivocal, and LTx should be reserved for those who do not respond to optimised therapy. Multisystem evaluation and lifelong surveillance is vital. @MarkGreerMD https://t.co/Zg2Y102SoJ https://t.co/KMiTvpTG4I
-
-
Mashup Score: 40Books | European Respiratory Society - 5 day(s) ago
If you have a myERS account, please click the button above to login. Not sure if your membership is up to date? Check at my. ersnet.org
Source: publications.ersnet.orgCategories: General Medicine News, PulmonologyTweet-
Lung transplantation (LTx) may be considered in end-stage COPD. Survival benefit is often equivocal, and LTx should be reserved for those who do not respond to optimised therapy. Multisystem evaluation and lifelong surveillance is vital. @MarkGreerMD https://t.co/Zg2Y102SoJ https://t.co/KMiTvpTG4I
-
-
Mashup Score: 4Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology - 5 day(s) ago
BackgroundLocal priming of the innate immune system with a Toll-like receptor (TLR)2/6 agonist may reduce morbidity and mortality associated with viral respiratory tract infections, particularly for the elderly and those with chronic diseases. The objectives of the present study were to understand the potential of prophylactic treatment with a TLR2/6 agonist as an enhancer of innate immunity pathways leading to accelerated respiratory virus clearance from the upper airways.MethodsTwo randomised, double-blind, placebo-controlled clinical trials were conducted in healthy adult participants. The first dose-escalation study assessed safety, tolerability and mechanistic biomarkers following single and repeated intranasal administrations of INNA-051. The second was an influenza A viral challenge study assessing the impact of treatment on host defence biomarkers and viral load.ResultsINNA-051 was well tolerated in both studies, with no dose-limiting toxicities identified. Mechanistic biomarke
Source: publications.ersnet.orgCategories: General Medicine News, PulmonologyTweet-
Early clinical trials of intranasal INNA-051 show its potential as a prophylactic that boosts innate immunity. The TLR2/6 agonist activated local pathways associated with antiviral host defence and accelerated viral clearance after influenza challenge. https://t.co/5kiNEOTSmY https://t.co/p5xQ9dRQF2
-
-
Mashup Score: 40Books | European Respiratory Society - 6 day(s) ago
If you have a myERS account, please click the button above to login. Not sure if your membership is up to date? Check at my. ersnet.org
Source: publications.ersnet.orgCategories: General Medicine News, PulmonologyTweet-
Lung transplantation (LTx) may be considered in end-stage COPD. Survival benefit is often equivocal, and LTx should be reserved for those who do not respond to optimised therapy. Multisystem evaluation and lifelong surveillance is vital. @MarkGreerMD https://t.co/Zg2Y102SoJ https://t.co/KMiTvpTG4I
-
-
Mashup Score: 0Lung function improvement on triple modulators: high-resolution, nationwide data from the Danish Cystic Fibrosis Cohort - 6 day(s) ago
BackgroundPeople living with cystic fibrosis in Denmark had early, universal access to triple modulator treatment with elexacaftor/tezacaftor/ivacaftor. Close monitoring allowed us to assess the impact of treatment on lung function and progression of lung disease in an unselected nationwide cystic fibrosis population from 6 years of age.MethodsData were analysed using linear mixed-effect models to assess changes in levels and annual rates of change (slopes) in percent predicted (pp) forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC) and forced expiratory flow at 25–75% of FVC (ppFEF25–75%) between the 12 months pre-treatment and treatment periods. Subgroup analyses assessed the impact of elexacaftor/tezacaftor/ivacaftor among those with/without previous modulator treatment, normal/mild/moderate/severe lung disease at treatment initiation, children/adults and birth cohorts.ResultsWe included 392 people living with cystic fibrosis with a median (interquartile range) 12 (
Source: publications.ersnet.orgCategories: General Medicine News, PulmonologyTweet-
ERJOR: This nationwide real-world study uses high-resolution data to document that elexacaftor/tezacaftor/ivacaftor halts progression of lung disease in cystic fibrosis, and improves lung function across all ages, disease severities and prior modulator use https://t.co/Y5g00tYKh0 https://t.co/CPy5gHonM4
-
-
Mashup Score: 40Books | European Respiratory Society - 7 day(s) ago
If you have a myERS account, please click the button above to login. Not sure if your membership is up to date? Check at my. ersnet.org
Source: publications.ersnet.orgCategories: General Medicine News, PulmonologyTweet-
Lung transplantation (LTx) may be considered in end-stage COPD. Survival benefit is often equivocal, and LTx should be reserved for those who do not respond to optimised therapy. Multisystem evaluation and lifelong surveillance is vital. @MarkGreerMD https://t.co/Zg2Y102SoJ https://t.co/KMiTvpTG4I
-
-
Mashup Score: 9Extracellular vesicles in sputum of children with cystic fibrosis pulmonary exacerbations - 7 day(s) ago
BackgroundThe aim of this study was to quantify mediators of neutrophilic inflammation within airway extracellular vesicles (EVs) of children treated for a cystic fibrosis (CF) pulmonary exacerbation (PEx).MethodsEVs were isolated from stored sputum samples collected before and after antibiotic therapy for PEx between 2011 and 2013, and characterised by nanoparticle tracking analysis (NTA) and transmission electron microscopy (TEM). Western blot analysis of EV protein extracts was used for EV canonical protein markers CD63, CD9 and flotillin-1 (FLOT1), as well as neutrophil elastase (NE), myeloperoxidase (MPO) and interleukin-8. The EV content of NE and MPO were expressed as ratios of NE/FLOT1 and MPO/FLOT1 protein band densities.ResultsSputum samples from 21 children aged 13.3 (range 8.0–17.0) years were analysed. NTA showed high concentrations of particles at the size of small EVs (50–200 nm), and typical EV morphology was confirmed by TEM. CD63, CD9 and FLOT1 were detectable in all
Source: publications.ersnet.orgCategories: General Medicine News, PulmonologyTweet-
ERJ Open Research: Extracellular vesicles (EVs) in cystic fibrosis airways contain NE and MPO. NE and MPO EV cargo increase with therapy for pulmonary exacerbations and changes in EV cargo correlate with measures of pulmonary function. https://t.co/m6elcBbk71 https://t.co/ZyVH9lggUP
-
Lung transplantation (LTx) may be considered in end-stage COPD. Survival benefit is often equivocal, and LTx should be reserved for those who do not respond to optimised therapy. Multisystem evaluation and lifelong surveillance is vital. @MarkGreerMD https://t.co/Zg2Y102SoJ https://t.co/KMiTvpTG4I